Clinical trials: Parkinson Disease, Mitochondrial
Parkinson's Disease (PD)
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
The main goal of the study is to investigate how well the new drug SUL-238 works in Parkinson's Disease (PD). This is done by means of an MRS scan. An MRS scan is similar to a regular MRI scan.
- Trial name
- SHEPHERD (NCT07322887)
- Testing
- SUL-238 (1500 mg t.i.d.) film-coated tablets, SUL-238 (500 mg t.i.d.) film-coated tablets
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.
Parkinson's Disease
Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease
Open-label study with 30-day run-in phase and adaptive design component to include more participants if deemed appropriate by investigators.
- Trial name
- NCT02462603
- Testing
- PTC-589
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- Edison Pharmaceuticals Inc